REGENXBIO Inc. (RGNX)

RGNX Investor Notice: Johnson Fistel Investigates REGENXBIO Inc. Following Clinical Hold

Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial

FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome

REGENXBIO Announces Regulatory Update on RGX-121 for MPS II

Regenxbio's Multi-Catalyst Setup Is Hard To Ignore (Rating Upgrade)

REGENXBIO Q2 Earnings Call Highlights

REGENXBIO Inc. (RGNX) Q2 2026 Earnings Call Transcript

Regenxbio (RGNX) Beats Q2 Earnings and Revenue Estimates

REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights

REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights

New Strong Sell Stocks for July 23rd

Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm

Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants

REGENXBIO Announces Proposed Public Offering of Common Stock

Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm

REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone

Regenxbio: 'Strong Buy' On FDA Course Reversal For NAVSUNLI And Potential AA DMD Filing